Lisata Therapeutics Inc. (LSTA)
$1.57
$0.08
(5.37%)
As on 01-Sep-2026 16:00EDT
Market cap
--
Revenue (TTM)
--
P/E Ratio
--
P/B Ratio
--
Div. Yield
--
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
--
-
ROE
--
-
ROCE
--
-
Industry P/E
--
-
EV/EBITDA
--
-
Debt to Equity
--
-
Book Value
--
-
EPS
--
-
Face value
--
-
Shares outstanding
--
10 Years Aggregate
CFO
$-241.84 Mln
EBITDA
$-306.87 Mln
Net Profit
$-292.38 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Lisata Therapeutics Inc (LSTA)
| -15.6 | 58.6 | -51.7 | -32.3 | -10.4 | -39.7 | -31.8 |
|
BSE Sensex
| -9.1 | -1.5 | 2.9 | -3.6 | 5.9 | 6.0 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
|---|---|---|---|
|
Lisata Therapeutics Inc (LSTA)
| -37.6 | 9.1 | 7.9 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Lisata Therapeutics Inc (LSTA)
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is... in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. Lisata Therapeutics, Inc. was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. in September 2022. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey. As of July 21, 2026, Lisata Therapeutics, Inc. operates as a subsidiary of Kuva Labs, Inc. Read more
-
President, CEO & Director
Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D.
-
President, CEO & Director
Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D.
-
Headquarters
Basking Ridge, NJ
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Lisata Therapeutics Inc (LSTA)
What is the current share price of Lisata Therapeutics Inc (LSTA) Today?
The share price of Lisata Therapeutics Inc (LSTA) is $1.57 (NASDAQ) as of 01-Sep-2026 16:00 EDT. Lisata Therapeutics Inc (LSTA) has given a return of -10.36% in the last 3 years.
What is the current PB & PE ratio of Lisata Therapeutics Inc (LSTA)?
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-0.97 |
1.09 |
2024 |
-1.24 |
0.84 |
2023 |
-1.07 |
0.46 |
2022 |
-0.23 |
0.19 |
2021 |
-0.12 |
0.04 |
What is the 52 Week High and Low of Lisata Therapeutics Inc (LSTA)?
The 52-week high and low of Lisata Therapeutics Inc (LSTA) are Rs 5.07 and Rs 0.99 as of 02-Sep-2026.
What is the market cap of Lisata Therapeutics Inc (LSTA)?
Lisata Therapeutics Inc (LSTA) has a market capitalisation of $ 15 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Lisata Therapeutics Inc (LSTA)?
Before investing in Lisata Therapeutics Inc (LSTA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.